Cannabis Genes Could Help Breeders Predict THC and CBD Yields

Cannabis cultivation is shifting from a trial-and-error agricultural guessing game to a predictable data science.

For decades, cannabis breeding has relied on a familiar formula: cross promising plants, grow them to maturity, analyze their cannabinoid profiles, and repeat the process over multiple generations. While this approach has produced remarkable cultivars, it also requires significant time, labor, and financial investment before growers know whether a plant will ultimately deliver the desired levels of THC or CBD.

Emerging research suggests that process may soon become far more precise. A 2026 study published in Industrial Crops and Products presents an integrated model that combines gene expression, genetic variants, and cannabinoid measurements to better explain why some cannabis plants consistently produce higher levels of THC or CBD than others. The findings point toward a future where molecular screening becomes an essential tool for cannabis breeding, helping producers identify superior cultivars before committing valuable greenhouse space and production resources. Let’s dive into the study and what it means for the future of growing cannabis.

Cannabis Breeding Is Entering the Genomics Era

Cannabis cultivation has become increasingly sophisticated as legal markets mature. Modern producers already rely on tissue culture, environmental monitoring, precision irrigation, and laboratory testing to improve consistency. Genetics may now become the next major competitive advantage.

Instead of evaluating thousands of plants solely through cultivation trials, breeders could eventually screen seedlings for specific molecular markers associated with desirable cannabinoid profiles. This represents an important shift in philosophy. Cannabis breeding is becoming less of a trial-and-error cultivation problem and more of a genomics challenge, where DNA sequence variations and gene activity provide early clues about a plant’s future performance. The researchers sought to better understand not only which genes determine whether a plant produces THC or CBD, but also why some varieties generate substantially higher cannabinoid yields than others.

Key Genes Determine THC and CBD Chemotypes

The study focused on two well-known cannabinoid synthase genes: THCAS, responsible for producing tetrahydrocannabinolic acid (THCA), and CBDAS, which produce cannabidiolic acid (CBDA). These acidic cannabinoids later convert into THC and CBD through decarboxylation.

The researchers found that the presence or absence of these genes largely defines whether a cannabis variety is THC-dominant, CBD-dominant, or balanced between the two. While this concept has been recognized previously, the recent study goes further by demonstrating that gene expression, the degree to which these genes are actively functioning, also plays an important role in determining the amount of cannabinoids a plant ultimately produces. Simply possessing the right genes is only part of the equation, while how strongly those genes are expressed can significantly influence final cannabinoid concentrations.

Multiple Data Sources Improved Predictions

Rather than relying on a single type of genetic information, the researchers built an integrated prediction model using several layers of biological data. They quantified THC and CBD levels in proprietary commercial cannabis varieties while combining those findings with genomic, transcriptomic, and metabolomic information from 27 publicly available cannabis accessions. Altogether, the study analyzed 157 RNA sequencing datasets alongside eight fully sequenced cannabis genomes.

This comprehensive approach allowed the team to examine not only genetic sequences but also how genes were functioning within the plant. The resulting models demonstrated strong predictive performance, showing that combining multiple molecular datasets provides a clearer picture of cannabinoid production than evaluating any single factor alone.

Gene Activity Helps Predict Cannabinoid Yield

One of the strongest findings was the positive relationship between cannabinoid synthase gene expression and actual cannabinoid production. Plants exhibiting higher expression of THCAS generally produced more THC, while increased CBDAS expression correlated with higher CBD levels.

The researchers also identified another important contributor: GOT1, a gene involved in producing the cannabinoid precursor cannabigerolic acid (CBGA). CBGA serves as the foundational molecule from which major cannabinoids are synthesized. Because both THC and CBD originate from this precursor, genes that influence CBGA production can indirectly affect overall cannabinoid yield.

When the researchers incorporated GOT1 into their predictive models, accuracy improved substantially for both THC and CBD production, highlighting the importance of evaluating the broader cannabinoid biosynthetic pathway rather than focusing exclusively on the final enzymes.

Genetic Variants Reveal Elite Cannabis Lines

Beyond measuring gene expression, the researchers examined different versions, known as alleles, of the cannabinoid synthase genes. They identified eight distinct THCAS alleles and five CBDAS alleles that helped distinguish cannabis chemotypes.

Some genetic variants appeared to outperform others. Three THCAS variants, THCASa3, THCASa4, and THCASa6, showed stronger associations with THC production than the commonly referenced THCAS allele found in UniProt databases. Meanwhile, the standard UniProt CBDAS allele remained strongly associated with CBD production.

Perhaps most notably, incorporating allele information dramatically improved the ability to predict CBD production. In fact, allele-based models outperformed models based solely on gene expression, demonstrating exceptionally strong predictive accuracy. For breeders, identifying specific genetic variants could become an effective way to select high-performing plants long before harvest.

• Haplotype Controls Chemotype: The presence or absence of functional THCAS and CBDAS genes serves as the absolute gatekeeper for whether a cultivar expresses a THC-dominant, CBD-dominant, or balanced profile.
• Expression Rules Yield: Total cannabinoid output varies heavily based on the transcription strength of the synthases and key upstream helper genes like GOT1 and GOT4, which feed the core CBGA precursor into the production pipeline.
• Alleles Drive Fine Tuning: Specific variant lineages carry enhanced potential; for instance, the THCASa3 and THCASa4 alleles show a significantly stronger correlation to high-tier THC yields than standard baseline database alleles.

Why Molecular Screening Could Transform Breeding

Traditional cannabis breeding often requires months of cultivation before cannabinoid testing reveals whether a new cross possesses commercial potential. Genetic screening could significantly shorten that timeline. Instead of growing large populations to maturity, breeders may eventually identify promising germplasm during early developmental stages using molecular markers associated with high THC or CBD production. This could reduce production costs, accelerate breeding programs, and improve consistency across commercial operations.

Medical cannabis producers can benefit particularly from these advances because standardized cannabinoid profiles are critical for patients, clinicians, and regulatory compliance. Selecting plants with predictable genetic characteristics could help improve batch-to-batch consistency while reducing variability throughout cultivation.

Rather than replacing traditional breeding expertise, genomic tools would complement existing practices by allowing breeders to make more informed selection decisions earlier in the process.

Precision Genetics in Cannabis Production

As cannabis science continues to evolve, breeding is increasingly being guided by molecular biology instead of observation alone. This study provides one of the most comprehensive views yet of how gene presence, gene expression, and genetic variation interact to influence cannabinoid production. By integrating these factors into predictive models, researchers demonstrated that cannabis chemotypes and cannabinoid yields can be estimated with remarkable accuracy.

While additional validation across broader cannabis populations will be important, the findings illustrate how genomics may reshape the industry’s future. Instead of waiting for mature flowers to reveal a plant’s potential, growers and breeders may soon screen cultivars for molecular markers before committing plants to full production cycles.

As precision breeding becomes more accessible, selecting elite cannabis genetics could increasingly begin in the laboratory rather than the greenhouse, making cannabis cultivation as much a science of genomics as it is a science of growing plants.

References:

^{1. Alberto Gila-Navarro, Aingeru Calderón, Juan-Pablo Huertas, Sergio Moreno, Julia Weiss, Marcos Egea-Cortines, An integrated view of haplotype, gene expression and allelic variation explains the chemotype and cannabinoid yield of Cannabis sativa, Industrial Crops and Products, Volume 249, 2026, 123750, ISSN 0926-6690, https://doi.org/10.1016/j.indcrop.2026.123750}